Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index

December 03, 2024 09:47 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Kong-Listed Biotech Index ("HSHKBIO"), effective December 9th, 2024, according to the announcement issued by Hang Seng Indexes Company Limited ("HSIL").
(https://www.hsi.com.hk/static/uploads/contents/en/news/pressRelease/20241122T174500.pdf)

Mr. Xie Fangmin, Chairman and CEO of Fangzhou, stated, "We are thrilled to be included in the Hang Seng Hong Kong-Listed Biotech Index. This inclusion will not only elevate the company's profile among a broader spectrum of investors, but also create opportunities for our customers, partners, and investors to engage with Fangzhou Inc.'s innovative Internet healthcare solutions and be part of our mission to enhance healthcare accessibility and delivery."

Fangzhou has been listed on the main board of the Hong Kong Stock Exchange since July 2024. As a pioneer in the Internet hospital sector, the Company is focused on chronic disease management and providing tailored medical care and precision medicine for a growing population of chronic disease patients.

About Hang Seng Hong Kong-Listed Biotech Index ("HSHKBIO")

In 2019 HSIL launched the Hang Seng Hong Kong Listed Biotech Index, which reflects the overall performance of biotech companies that are listed in Hong Kong, including stocks listed through Chapter 18A of the Listing Rules of Stock Exchange of Hong Kong Limited. HSHKBIO includes the 50 largest companies that are classified as "Biotechnology", "Pharmaceuticals", and "Medical Devices" in the Hang Seng Industry Classification System ("HSICS").

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of June 30, 2024), the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details, visit https://investors.jianke.com.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: [email protected] 

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.